Search results for

The state's Cannabis Control Board could vote Friday to waive license fees for farmers who got into the legal market early, saying they "suffered a sufficient need for financial assistance." But cannabis farmers say more relief is needed.

ProPublica reporter Jesse Eisinger says that the government undermines the notion of equity and fails to deter crime when it allows large corporations to settle lawsuits by paying fines.

New York Times reporter Scott Shane discusses special counsel Robert Mueller's indictment of 13 Russians who allegedly participated in a complex social media operation to undermine the 2016 election.

Most fisheries certified by the MSC system have conditions that spell out how they have to change their operations to comply with MSC standards. But they can still be labeled "certified sustainable seafood" even though they have years to comply.

RealtyTrac is showing a 14 percent rise in first time default notices between July and September. It's the first jump after five consecutive quarterly declines, suggesting that banks are gradually addressing their backlog of foreclosed homes. Michel Martin discusses the causes and impact of the mortgage crisis with industry observer and history professor Beryl Satter.

Local police often don't feel equipped to investigate cybercrime. The NYPD is trying to teach patrol officers to ask the right questions about IP addresses, Bitcoin and phone spoofing.

Blurring the line between church and state threatens civil liberties and privacy, says former president Jimmy Carter. That's the case he makes in his new book, Our Endangered Values: America's Moral Crisis.

Senators heard from witnesses, ranging from judicial ethics experts to a former attorney general in the George W. Bush administration, but used their questioning to reinforce their own arguments.

Most of the victims were women of Asian descent. Authorities say it's too early to declare the attacks a hate crime – but advocates say there's a pattern that can't be ignored.

Merck documents show that in 2000, the maker of Vioxx tried to censor critics of the drug's safety. That was the year that drug giant Merck learned that Vioxx might cause heart attacks and other problems. The documents show a concerted effort by the company to identify doctors who were raising questions about the drug's safety and to put pressure on them to stop making critical comments. A spokesman for Merck denies the allegations.